## **Core Concept**
The management of pulmonary embolism (PE) involves stabilizing the patient, oxygen therapy, and anticoagulation to prevent further clot formation and allow the body to dissolve the existing clot. The choice of anticoagulant or thrombolytic therapy depends on the severity of the PE, patient risk factors, and specific clinical scenarios.

## **Why the Correct Answer is Right**
The correct approach for treating pulmonary embolism often involves anticoagulation. Low molecular weight heparin (LMWH) or unfractionated heparin (UFH) are commonly used as initial treatments for PE. In some cases, especially with massive PE or when there's hemodynamic instability, thrombolytic therapy might be considered. However, for many patients, especially those without hemodynamic instability, **anticoagulation with heparin (or LMWH) and sometimes direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, or warfarin** are mainstays of treatment.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but typically incorrect options might include treatments not standard for PE, such as certain antibiotics or antihypertensives not used in acute PE management.
- **Option B:** Similarly, without specifics, if this option does not align with standard PE treatment protocols (e.g., using a medication not indicated for PE), it would be incorrect.
- **Option C:** If this option suggests a treatment not typically used for PE, such as a specific antibiotic or an anti-arrhythmic, it would be incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **risk stratification** is crucial in managing PE. Patients with hemodynamically stable PE but with evidence of right ventricular strain or elevated biomarkers (like troponin or BNP) might benefit from closer monitoring and possibly more aggressive treatment. Always consider the patient's renal function when choosing anticoagulants, especially when considering DOACs or LMWH.

## **Correct Answer: D.**